Opiant Pharmaceuticals, Inc., a specialty pharmaceutical company, develops medicines for addictions and drug overdose. The company offers NARCAN nasal spray, a treatment to reverse opioid overdoses. Its pipeline of product candidates includes medicines for the treatment for opioid overdose reversal; alcohol use disorders; acute cannabinoid overdose; and opioid use disorders. The company was formerly known as Lightlake Therapeutics Inc. and changed its name to Opiant Pharmaceuticals, Inc. in January 2016. Opiant Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Santa Monica, California.
IPO Year:
Exchange: NASDAQ
Website: opiant.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/9/2021 | $42.00 | Outperform | Oppenheimer |
Oppenheimer initiated coverage of Opiant Pharmaceuticals with a rating of Outperform and set a new price target of $42.00